Investment

Regulatory Science

Cardiawave begins routine EU rollout of Valvosoft aortic stenosis device

The French medtech has treated its first routine patients in France, the Netherlands and Germany with its non-invasive ultrasound device for severe aortic stenosis.
The French medtech has treated its first routine patients in France, the Netherlands and Germany with its non-invasive ultrasound device for severe aortic stenosis.
The Biotech Times Editorial Team  · 

Enterome EO2463 hits 74% ORR in iNHL combo cohort at EHA 2026

Interim SIDNEY trial data show durable CD8 T cell responses and a 41% monotherapy ORR in indolent non-Hodgkin lymphoma patients on watchful waiting.
Interim SIDNEY trial data show durable CD8 T cell responses and a 41% monotherapy ORR in indolent non-Hodgkin lymphoma patients on watchful waiting.
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health
Genomics

Nano Dimension signs term sheet to merge with Infinite Epigenetics

Nano Dimension is pivoting from digital manufacturing into epigenetic diagnostics via a proposed $890m combination with AI-powered Infinite Epigenetics.
Nano Dimension is pivoting from digital manufacturing into epigenetic diagnostics via a proposed $890m combination with AI-powered Infinite Epigenetics.
The Biotech Times Editorial Team  · 
Biotech

VERAXA Biotech lists on Nasdaq via SPAC merger, raises $77.5m

The Swiss oncology biotech completes its Voyager Acquisition Corp. merger and begins trading under "VRXA" on 11 June 2026.
The Swiss oncology biotech completes its Voyager Acquisition Corp. merger and begins trading under "VRXA" on 11 June 2026.
The Biotech Times Editorial Team  · 
Diagnostics

Eliaz Therapeutics opens Reg CF round to fund sepsis apheresis device

The California biotech is crowdfunding to advance XGal-3, an FDA Breakthrough Device-designated apheresis system targeting Galectin-3 in sepsis.
The California biotech is crowdfunding to advance XGal-3, an FDA Breakthrough Device-designated apheresis system targeting Galectin-3 in sepsis.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biotech

Parabilis Medicines raises $745m in upsized Nasdaq IPO

The Cambridge biotech priced 33.5 million shares at $20 each, with Regeneron taking a concurrent $75m private placement stake.
The Cambridge biotech priced 33.5 million shares at $20 each, with Regeneron taking a concurrent $75m private placement stake.
The Biotech Times Editorial Team  · 
Diagnostics

Vivoryon touts DKD kidney data as it hunts Phase 2b partner

The Dutch biotech reported compelling eGFR data in diabetic kidney disease patients and confirmed cash runway only into Q4 2026 as partnership talks continue.
The Dutch biotech reported compelling eGFR data in diabetic kidney disease patients and confirmed cash runway only into Q4 2026 as partnership talks continue.
The Biotech Times Editorial Team  · 
Genomics

AC Immune gets $4m Goradia grant to extend Parkinson's vaccine trial

The philanthropic grant extends Part 1 of the Phase 2 VacSYn trial of ACI-7104 by two years, with final Part 1 data due in
The philanthropic grant extends Part 1 of the Phase 2 VacSYn trial of ACI-7104 by two years, with final Part 1 data due in
The Biotech Times Editorial Team  · 
Bioprocessing

Neion Bio closes $23m Series A for egg-based biologics platform

The New York biotech raised an oversubscribed Series A led by Caffeinated Capital to scale its Raptor egg-based biomanufacturing platform.
The New York biotech raised an oversubscribed Series A led by Caffeinated Capital to scale its Raptor egg-based biomanufacturing platform.
The Biotech Times Editorial Team  · 
Biotech

Shattuck Labs prices $75m public offering to fund DR3 programme

Shattuck Labs priced a $75 million public offering of shares and pre-funded warrants, with proceeds set to advance its DR3 antibody pipeline.
Shattuck Labs priced a $75 million public offering of shares and pre-funded warrants, with proceeds set to advance its DR3 antibody pipeline.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy

SL Bio completes SPAC merger, lists on Nasdaq as SL Science

The Taiwan-based cell therapy company closes its Horizon Space SPAC combination, debuting on Nasdaq under ticker SLBT with a $5.6bn implied valuation.
The Taiwan-based cell therapy company closes its Horizon Space SPAC combination, debuting on Nasdaq under ticker SLBT with a $5.6bn implied valuation.
The Biotech Times Editorial Team  · 
Genomics

Kyntra Bio roxadustat shows TI benefit in LR-MDS regardless of RS status

Post-hoc MATTERHORN data presented at EHA 2026 show roxadustat achieved transfusion independence in both RS-positive and RS-negative lower-risk MDS patients.
Post-hoc MATTERHORN data presented at EHA 2026 show roxadustat achieved transfusion independence in both RS-positive and RS-negative lower-risk MDS patients.
The Biotech Times Editorial Team  · 
Digital Health

Nyxoah raises $110m to accelerate Genio sleep apnoea launch in US

The Belgian medtech closed a $95m equity round and expects a $15m EIB loan tranche as it scales its FDA-approved Genio neurostimulator commercially.
The Belgian medtech closed a $95m equity round and expects a $15m EIB loan tranche as it scales its FDA-approved Genio neurostimulator commercially.
The Biotech Times Editorial Team  · 
Biotech

Linnaeus Therapeutics' LNS8801 selected for NIA lifespan testing

The GPER agonist joins the NIA's Interventions Testing Programme, complementing a separate $22m ARPA-H contract to evaluate healthspan preservation.
The GPER agonist joins the NIA's Interventions Testing Programme, complementing a separate $22m ARPA-H contract to evaluate healthspan preservation.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Kymera Therapeutics doses first participant in IRAK4 degrader trial

KT-485's Phase 1 first-in-human start triggers a $20m milestone payment from Sanofi under their IRAK4 degrader collaboration.
KT-485's Phase 1 first-in-human start triggers a $20m milestone payment from Sanofi under their IRAK4 degrader collaboration.
The Biotech Times Editorial Team  · 

Standard BioTools and Treeline Biosciences agree all-stock merger

The combined company will operate as Treeline Biosciences, with over $900m in cash and three Phase 1 oncology programmes already under way.
The combined company will operate as Treeline Biosciences, with over $900m in cash and three Phase 1 oncology programmes already under way.
The Biotech Times Editorial Team  · 
Regulatory Science

Agios licenses SYK inhibitor cevidoplenib from Oscotec in $1bn ITP deal

Agios will pay $25m upfront for global rights to cevidoplenib, a next-generation oral SYK inhibitor targeting immune thrombocytopenia, with Phase 3 planned for 2028.
Agios will pay $25m upfront for global rights to cevidoplenib, a next-generation oral SYK inhibitor targeting immune thrombocytopenia, with Phase 3 planned for 2028.
The Biotech Times Editorial Team  · 
Biotech

GNI Group to acquire Ayumi Pharmaceutical in ¥44.8bn deal

The Tokyo-listed biopharmaceutical group is buying Blackstone's Japanese specialty pharma asset to build a cross-Pacific commercial platform.
The Tokyo-listed biopharmaceutical group is buying Blackstone's Japanese specialty pharma asset to build a cross-Pacific commercial platform.
The Biotech Times Editorial Team  · 
Digital Health

Health Catalyst divests Vitalware to Med-Metrix for $147m

Health Catalyst will sell its mid-revenue cycle unit to fund AI investment and fully repay a $160m term loan.
Health Catalyst will sell its mid-revenue cycle unit to fund AI investment and fully repay a $160m term loan.
The Biotech Times Editorial Team  · 
Biotech

Nurix and Roche strike $2.3bn BTK degrader collaboration

Nurix Therapeutics receives $700m upfront from Roche to co-develop bexobrutideg across blood cancers, multiple sclerosis and urticaria.
Nurix Therapeutics receives $700m upfront from Roche to co-develop bexobrutideg across blood cancers, multiple sclerosis and urticaria.
The Biotech Times Editorial Team  · 
Subscribe to Investment